A whistleblower suit alleging off-label promotion of a blood thinning drug has been dismissed by a federal judge in Chicago.

The suit, filed under the qui tam provisions of the federal False Claims Act, alleged that Aventis promoted off-label uses of Lovenox, thereby inducing doctors and hospitals to submit fraudulent Medicare claims.

Judge Matthew Kennelly ruled that Medicare claims filed as a result of the alleged off-label scheme were not “material” to the amount the government paid for treatment of any patient. He found that because Medicare reimbursement was based on a diagnosis group code tied to a patient diagnosis and age, and not tied to services given a patient, the Medicare claims could not have been false.

Let us help you.
Get a free, confidential case review